Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be
administered in combination with immunotherapy drugs including urelumab, cabiralizumab and
nivolumab .